

Bio Products Laboratory

Memorandum

To: R.C.D. Walker
C. Hadfield
Dr T.J. Snape

Dr M.J. Harvey
B. Chapman
C. Ronaldson

Our ref: CHD/ME

cc:

Ext. No.: GRO-C

From: Dr C.H. Dash

Date: 6 September, 1996

Subject: REPLENATE® recall

I have spoken to Dr Dasani following his critical letter. I think he now understands what we did and why. However, two issues remain:

1. He believes that we should offer follow-up HCV screening for recipients of this batch. He says other haemophilia directors have expressed the same view to him.
2. The recall has weakened confidence, rather than improved public confidence in our products. This is the reverse of what we said was intended in our initial release.

I would think that offering anti-HCV test on recipients of the batch of REPLENATE® might help us regain some confidence among haemophiliacs and their carers.

Comments?

GRO-C: Dash

BPL Quality Control	
DATE	- 9 SEP 1996
ACTION	Rita: talk to me about a reply.
FILING	① Recall master file with SJS ② HCV litigation file ✓